RxDoctor Payments Data

David Hill, DO

Family Medicine · Cuero, TXNPI 1447228135

Payments from drug & device makers

$2,408in general payments, 2019–2025

Across 141 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$176
  • Novartis$175
  • Teva Pharmaceuticals USA, Inc.$162
  • Amgen$145
  • Boehringer Ingelheim$140
  • Astellas Pharma US Inc$132
  • plus $1K from 37 others

What the payments were for

  • Food & beverage$2,30396%
  • Education$1054%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,408 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$4,766
Medicare patients
79
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$67,985
TrulicityDulaglutide51$48,096
JardianceEmpagliflozin51$44,351
OzempicSemaglutide35$32,114
FarxigaDapagliflozin Propanediol23$31,052
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$28,611
GlyxambiEmpagliflozin/Linagliptin21$26,088
MounjaroTirzepatide22$22,902
TradjentaLinagliptin28$21,502
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen565$20,803
MyrbetriqMirabegron20$20,108
LinzessLinaclotide31$18,891
XareltoRivaroxaban17$18,002
Combivent RespimatIpratropium/Albuterol Sulfate27$13,979
EntrestoSacubitril/Valsartan18$13,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Combivent Respimat$140$105,920127 claims
Lilly USA, LLCTrulicity, Mounjaro$130$70,99873 claims
PfizerEliquis$80$67,98569 claims
AstraZenecaFarxiga, Symbicort$28$36,79742 claims
Novo NordiskOzempic$102$32,11435 claims
AbbVieLinzess, Namzaric$64$26,39444 claims
Astellas Pharma US IncMyrbetriq$132$20,10820 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$100$19,97539 claims
Johnson & JohnsonXarelto$39$18,00217 claims
NovartisEntresto$175$13,45018 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$53$12,03014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cuero

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →